A novel GABAergic dysfunction in human Dravet syndrome

被引:49
|
作者
Ruffolo, Gabriele [1 ]
Cifelli, Pierangelo [1 ,2 ]
Roseti, Cristina [3 ]
Thom, Maria [4 ]
van Vliet, Erwin A. [5 ,6 ]
Limatola, Cristina [1 ,2 ]
Aronica, Eleonora [5 ,7 ]
Palma, Eleonora [1 ,3 ]
机构
[1] Sapienza Univ Rome, Pasteur Inst, Dept Physiol & Pharmacol, Cenci Bolognetti Fdn, Rome, Italy
[2] IRCCS Neuromed, Pozzilli, Italy
[3] IRCCS San Raffaele Pisana, Rome, Italy
[4] UCL, Dept Clin & Expt Epilepsy, Inst Neurol, London, England
[5] Univ Amsterdam, Dept Neuro Pathol, Amsterdam UMC, Amsterdam Neurosci, Amsterdam, Netherlands
[6] Univ Amsterdam, Swammerdam Inst Life Sci, Ctr Neurosci, Amsterdam, Netherlands
[7] SEIN, Heemstede, Netherlands
关键词
cannabidiol; epilepsy; GABA(A) receptor; GABA(A) reversal potential; human brain tissue; DRUG-RESISTANT SEIZURES; GABA(A) RECEPTOR; TUBEROUS SCLEROSIS; NEUROTRANSMITTER RECEPTORS; SUBUNIT EXPRESSION; ANOMALOUS LEVELS; XENOPUS OOCYTES; CL-TRANSPORTERS; MOUSE MODEL; CANNABIDIOL;
D O I
10.1111/epi.14574
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective Dravet syndrome is a rare neurodevelopmental disease, characterized by general cognitive impairment and severe refractory seizures. The majority of patients carry the gene mutation SCN1A, leading to a defective sodium channel that contributes to pathogenic brain excitability. A gamma-aminobutyric acid (GABAergic) impairment, as in other neurodevelopmental diseases, has been proposed as an additional mechanism, suggesting that seizures could be alleviated by GABAergic therapies. However, up to now the physiological mechanisms underlying the GABAergic dysfunction in Dravet syndrome are still unknown due to the scarce availability of this brain tissue. Here we studied, for the first time, human GABA(A)-evoked currents using cortical brain tissue from Dravet syndrome patients. Methods Results We transplanted in Xenopus oocytes cell membranes obtained from brain tissues of autopsies of Dravet syndrome patients, tuberous sclerosis complex patients as a pathological comparison, and age-matched controls. Additionally, experiments were performed on oocytes expressing human alpha 1 beta 2 gamma 2 and alpha 1 beta 2 GABA(A) receptors. GABA(A) currents were recorded using the two-microelectrodes voltage-clamp technique. Quantitative real-time polymerase chain reaction, immunohistochemistry, and double-labeling techniques were carried out on the same tissue samples. We found (1) a decrease in GABA sensitivity in Dravet syndrome compared to controls, which was related to an increase in alpha 4- relative to alpha 1-containing GABA(A) receptors; (2) a shift of the GABA reversal potential toward more depolarizing values in Dravet syndrome, and a parallel increase of the chloride transporters NKCC1/KCC2 expression ratio; (3) an increase of GABA(A) currents induced by low doses of cannabidiol both in Dravet syndrome and tuberous sclerosis complex comparable to that induced by a classical benzodiazepine, flunitrazepam, that still persists in gamma-less GABA(A) receptors. Significance Our study indicates that a dysfunction of the GABAergic system, considered as a feature of brain immaturity, together with defective sodium channels, can contribute to a general reduction of inhibitory efficacy in Dravet brain, suggesting that GABA(A) receptors could be a target for new therapies.
引用
收藏
页码:2106 / 2117
页数:12
相关论文
共 50 条
  • [1] Dravet Syndrome and Mitochondrial Dysfunction
    Castro-Gago, Manuel
    Perez-Gay, Laura
    Eiris-Punal, Jesus
    JOURNAL OF CHILD NEUROLOGY, 2011, 26 (10) : 1331 - 1332
  • [2] Epigenetic insights into GABAergic development in Dravet Syndrome iPSC and therapeutic implications
    Schuster, Jens
    Lu, Xi
    Dang, Yonglong
    Klar, Joakim
    Wenz, Amelie
    Dahl, Niklas
    Chen, Xingqi
    ELIFE, 2024, 12
  • [3] Corticohippocampal circuit dysfunction in a mouse model of Dravet syndrome
    Mattis, Joanna
    Somarowthu, Ala
    Goff, Kevin M.
    Jiang, Evan
    Yom, Jina
    Sotuyo, Nathaniel
    Mcgarry, Laura M.
    Feng, Huijie
    Kaneko, Keisuke
    Goldberg, Ethan M.
    ELIFE, 2022, 11
  • [4] A novel mouse model of Dravet syndrome.
    Minh Hieu Tran
    Ure, Kerstin
    Schock, Sarah
    Dyment, David
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2019, 44 (05): : S10 - S11
  • [5] Novel pharmacological targets for GABAergic dysfunction in ADHD
    Ferranti, Anthony S.
    Luessen, Deborah J.
    Niswender, Colleen M.
    NEUROPHARMACOLOGY, 2024, 249
  • [6] Cortico-Hippocampal Circuit Dysfunction in a Mouse Model of Dravet Syndrome
    Mattis, Joanna
    Somarowthu, Ala
    Goff, Kevin M.
    Yom, Jina
    Sotuyo, Nathaniel
    Feng, Huijie
    Kaneko, Keisuke
    McGarry, Laura
    Goldberg, Ethan M.
    ANNALS OF NEUROLOGY, 2021, 90 : S117 - S117
  • [7] Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome
    Buck, Marcia L.
    Goodkin, Howard P.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (11) : 1136 - 1144
  • [8] Proteomic characterization of a novel mouse model of Dravet syndrome
    Miljanovic, Nina
    Hauck, Stefanie M.
    van Dijk, R. Maarten
    Rezaei, Ali
    Potschka, Heidrun
    EPILEPSIA, 2021, 62 : 271 - 272
  • [9] Fragile X Syndrome: The GABAergic System and Circuit Dysfunction
    Paluszkiewicz, Scott M.
    Martin, Brandon S.
    Huntsman, Molly M.
    DEVELOPMENTAL NEUROSCIENCE, 2011, 33 (05) : 349 - 364
  • [10] GABAergic dysfunction mediates motor impairment in Rett syndrome
    Dubbioso, R.
    Bernardo, P.
    Coppola, A.
    Bravaccio, C.
    Manganelli, F.
    Di Lazzaro, V.
    Cobb, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 59 - 59